ALAN WELLS
Medical Practice in Pittsburgh, PA

8318479, Nov 27, 2012

May 19, 2005

11/133092

Karel Domansky - Cambridge MA, US
Linda G. Griffith - Cambridge MA, US
Steven R. Tannenbaum - Framingham MA, US
Alan Wells - Pittsburgh PA, US
Samuel Walker Inman - Boston MA, US

Massachusetts Institute of Technology - Cambridge MA
Univeristy of Pittsburgh—Of the Commonwealth System of Higher Education - Pittsburgh PA

C12M 1/22, C12M 3/00, C12M 1/34

4353052, 4353841, 4352873, 4352882, 4352883, 4352885, 4352931, 4353051, 4352991, 4353071

A system has been constructed that recapitulate the features of a capillary bed through normal human tissue. The system facilitates perfusion of three-dimensional (3D) cell monocultures and heterotypic cell co-cultures at the length scale of the capillary bed. A major feature is that the system can be utilized within a “multiwell plate” format amenable to high-throughput assays compatible with the type of robotics commonly used in pharmaceutical development. The system provides a means to conduct assays for toxicology and metabolism and as a model for human diseases such as hepatic diseases, including hepatitis, exposure-related pathologies, and cancer. Cancer applications include primary liver cancer as well as metastases. The system can also be used as a means of testing gene therapy approaches for treating disease and inborn genetic defects.

8029774, Oct 4, 2011

Jul 1, 2006

11/479627

Eric J. Beckman - Aspinwall PA, US
Stephen F. Badylak - Pittsburgh PA, US
Alan H. Wells - Pittsburgh PA, US
Jianying Zhang - Pittsburgh PA, US
Donald Freytes - Pittsburgh PA, US

University of Pittsburgh - Pittsburgh PA

A61K 31/74, A61K 38/39, A61K 38/00, A61K 47/48, A61F 2/00, A61P 17/02, C08G 63/48, C08G 63/91, C08L 89/00

424 7808, 424426, 514 172, 525 541

A composition includes at least one biologically active agent covalently attached to a first polymerizing molecule that is adapted to undergo a free radical polymerization. The first polymerizing molecule retains the ability to undergo free radical polymerization after attachment of the bioactive agent thereto. The first polymerizing molecule is preferably biocompatible. The polymerizing molecule can, for example. be dihydroxyphenyl-L-alanine (DOPA) or tyrosine. The composition can also include a second component synthesized by reacting at least one core molecule having a plurality of reactive hydrogen groups with at least one multi-isocyanate functional molecule to create a conjugate including terminal isocyanate groups. The conjugate molecule is reacted with a second polymerizing molecule that is adapted to undergo a free radical polymerization. The second polymerizing molecule includes a reactive hydrogen to react with the isocyanate groups of the conjugate.

2013005, Feb 28, 2013

Aug 26, 2011

13/219375

Jesse Jaynes - Auburn AL, US
Timothy Turner - Auburn AL, US
Alan Wells - Pittsburgh PA, US
Richard J. Bodnar - Pittsburgh PA, US

A61K 38/19, A61P 9/00, A61P 43/00, A61P 35/00

514 133, 514 192, 514 193, 514 214, 514 209

Disclosed are peptides having activity against receptor CXCR3 are disclosed that exhibit activity in preventing the formation of new vessels and activity in mediating the dissociation of newly-formed vessels and resolving of wounds in the later stages of wound healing. Preferred peptides are derived from the α-helix portion IP-10 (CXCL10) or from IP-9 (CXCL11), are nontoxic, and smaller than naturally occurring peptides, making them useful in therapies against diseases or disease states marked by unwanted angiogenesis, including tumorogenic diseases such as cancers, and in healing of chronic wounds.